Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00143039 · ClinicalTrials.gov registry record
Amniotic Fluid Tandem Mass Spectrometry for Pregnancies Complicated by NIH and Severe Symmetrical IUGR
A clinical trial, sponsored by Obstetrix Medical Group.
- Terminated
- Registry status
- 48
- Enrollment target
NCT00143039: Clinical Trial study, sponsored by Obstetrix Medical Group.
NCT00143039 is a clinical trial that was terminated before completion, run by Obstetrix Medical Group. The registered enrollment target is 48 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00143039 was terminated before completion, sponsored by Obstetrix Medical Group.
- TERMINATED
- Registry status
- 48 participants
- Enrollment target
Study Summary
The objective of this pilot study is to prospectively evaluate amniotic fluid of pregnancies complicated by non-immune hydrops and severe symmetrical intrauterine growth restriction by tandem mass spectrometry for inborn errors of metabolism.
Primary Outcome
Will assess whether amniotic fluid tandem mass spectrometry results are valid when compared to neonatal blood samples for normal pregnancies and those pregnancies complicated by NIH and severe symmetrical IUGR.
Interventions
- PROCEDURE Tandem MS test for inborn errors of metabolism
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2006-03 |
| Est. Completion | 2009-08 |
Why NCT00143039 stopped before completion
NCT00143039 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 48 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Tandem MS test for inborn errors of metabolism is the first listed.
NCT00143039 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00143039 about?
NCT00143039 is a clinical study titled "Amniotic Fluid Tandem Mass Spectrometry for Pregnancies Complicated by NIH and Severe Symmetrical IUGR". The objective of this pilot study is to prospectively evaluate amniotic fluid of pregnancies complicated by non-immune hydrops and severe symmetrical intrauterine growth restriction by tandem mass spectrometry for inborn errors of metabolism.
What is the current status of trial NCT00143039?
This trial is currently terminated. The enrollment target is 48 participants. The study started on 2006-03. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00143039?
The interventions under investigation include: Tandem MS test for inborn errors of metabolism (PROCEDURE).
Who is sponsoring clinical trial NCT00143039?
This trial is sponsored by Obstetrix Medical Group, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia